These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 25518355)

  • 1. [Targeted radionuclide therapy for castration-resistant prostate cancer].
    Nakamura K; Ohga S; Sasaki T; Baba S; Honda H
    Nihon Rinsho; 2014 Dec; 72(12):2181-5. PubMed ID: 25518355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review.
    Jong JM; Oprea-Lager DE; Hooft L; de Klerk JM; Bloemendal HJ; Verheul HM; Hoekstra OS; van den Eertwegh AJ
    Eur Urol; 2016 Sep; 70(3):416-26. PubMed ID: 26391636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice.
    Morgan SC
    J Med Imaging Radiat Sci; 2019 Dec; 50(4S1):S26-S30. PubMed ID: 31231006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Radium-223 treatment of bone metastases from castration-resistant prostate cancer].
    Mortensen J; Højgaard L
    Ugeskr Laeger; 2014 Jul; 176(30):1399-402. PubMed ID: 25292232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?
    Dorff TB; Gross ME
    Am Soc Clin Oncol Educ Book; 2015; ():e270-3. PubMed ID: 25993185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
    Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
    Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
    Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
    Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases].
    Tauber R; Gschwend J; Scheidhauer K; Eiber M; Krönke M
    Urologe A; 2017 Jan; 56(1):24-31. PubMed ID: 28058455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radium-223 dichloride in clinical practice: a review.
    Florimonte L; Dellavedova L; Maffioli LS
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data.
    Ryan CJ; Saylor PJ; Everly JJ; Sartor O
    Oncologist; 2014 Oct; 19(10):1012-8. PubMed ID: 25232039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
    Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
    J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radium-223 in metastatic castration resistant prostate cancer.
    Vuong W; Sartor O; Pal SK
    Asian J Androl; 2014; 16(3):348-53. PubMed ID: 24713838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
    Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
    JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer.
    Li J; Armstrong AJ
    Clin Adv Hematol Oncol; 2015 May; 13(5):293-8. PubMed ID: 26352773
    [No Abstract]   [Full Text] [Related]  

  • 16. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Nilsson S
    Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.
    Küronya Z; Sinkovics I; Ágoston P; Bíró K; Bodrogi I; Böde I; Dank M; Gyergyay F; Vajdics T; Kolonics Z; Nagyiványi K; Rúzsa Á; Géczi L
    Pathol Oncol Res; 2017 Oct; 23(4):777-783. PubMed ID: 28074331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.
    De Luca R; Costa RP; Tripoli V; Murabito A; Cicero G
    Oncology; 2018; 94(3):161-166. PubMed ID: 29241166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic changes of bone metastasis predict bone-predominant status to benefit from radium-223 dichloride for patients with castration-resistant prostate cancer.
    Hashimoto K; Miyoshi Y; Shindo T; Hori M; Tsuboi Y; Kobayashi K; Fukuta F; Tanaka T; Miyamoto S; Maehana T; Okada M; Nishiyama N; Yanase M; Kato R; Hotta H; Kunishima Y; Takahashi A; Hinotsu S; Sakata KI; Kitamura H; Uemura H; Masumori N
    Cancer Med; 2020 Nov; 9(22):8579-8588. PubMed ID: 32964674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
    Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
    Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.